Make your prediction
Buy inPayout
$100
$106
Buy prediction

About

If the difference between KT-621’s and placebo’s Week 16 EASI-75 response rates in the Phase 2b BROADEN2 trial (NCT07217015), as reported in the Initial Disclosure on or before Dec 31, 2026 at 11:59:59 PM ET, is above 30.0 percentage points, then the market resolves to Yes. The trial is the Phase 2b BROADEN2 trial (NCT07217015). The endpoint is Week 16 EASI-75. The qualifying Initial Disclosure must occur on or before Dec 31, 2026 at 11:59:59 PM ET. AppliedXL is the settlement source. The value is the drug’s reported responder percentage minus placebo’s reported responder percentage, not a sponsor-reported adjusted treatment difference or p-value. Where no dose or treatment arm is specified for KT-621, use the largest difference among individually reported active arms in the Initial Disclosure; pooled arms and combination regimens are excluded unless explicitly specified. Later-disclosed arms do not count. The sponsor-designated primary analysis governs; otherwise use missing-as-nonresponder analysis across the full randomized/full analysis population, then the largest reported population. Use reported percentage precision without rounding the difference. If only counts are reported, calculate each response rate and round it to one decimal place as specified in the rulebook; reported percentages govern over inconsistent counts. A qualitative success announcement, interim analysis, subgroup/post-hoc analysis, open-label extension, or disclosure containing only a treatment difference does not qualify. No Initial Disclosure by the deadline resolves every threshold No. If an initial publication has a material error and no reliable data is available by expiration, the rulebook’s last-fair-price provision applies. No No-data strike is included. Expiration moves earlier under Rule 7.2 when the Initial Disclosure occurs; latest expiration and last trading time are 10:00 AM ET seven calendar days after the disclosure deadline date. Full TRIALEFFICACY terms govern corrections and all other contingencies.

If the difference between KT-621’s and placebo’s Week 16 EASI-75 response rates in the Phase 2b BROADEN2 trial (NCT07217015), as reported in the Initial Disclosure on or before Dec 31, 2026 at 11:59:59 PM ET, is above 30.0 percentage points, then the market resolves to Yes. The trial is the Phase 2b BROADEN2 trial (NCT07217015). The endpoint is Week 16 EASI-75. The qualifying Initial Disclosure must occur on or before Dec 31, 2026 at 11:59:59 PM ET. AppliedXL is the settlement source. The value is the drug’s reported responder percentage minus placebo’s reported responder percentage, not a sponsor-reported adjusted treatment difference or p-value. Where no dose or treatment arm is specified for KT-621, use the largest difference among individually reported active arms in the Initial Disclosure; pooled arms and combination regimens are excluded unless explicitly specified. Later-disclosed arms do not count. The sponsor-designated primary analysis governs; otherwise use missing-as-nonresponder analysis across the full randomized/full analysis population, then the largest reported population. Use reported percentage precision without rounding the difference. If only counts are reported, calculate each response rate and round it to one decimal place as specified in the rulebook; reported percentages govern over inconsistent counts. A qualitative success announcement, interim analysis, subgroup/post-hoc analysis, open-label extension, or disclosure containing only a treatment difference does not qualify. No Initial Disclosure by the deadline resolves every threshold No. If an initial publication has a material error and no reliable data is available by expiration, the rulebook’s last-fair-price provision applies. No No-data strike is included. Expiration moves earlier under Rule 7.2 when the Initial Disclosure occurs; latest expiration and last trading time are 10:00 AM ET seven calendar days after the disclosure deadline date. Full TRIALEFFICACY terms govern corrections and all other contingencies.

Loading
Loading
Loading
Loading
Loading
Loading
Loading
Loading
Loading
Loading

Key stats

Expiry
Jan 7, 2027(47 days)
Interest
$12,973.12
Vol (24H)
$6,486.56→ 0.00%
Total
$6.5K

Details

Timeline & rules

Timeline & payout

This market will close and expire when an outcome occurs. Otherwise, it closes by Jan 7, 2027, 3:00 PM GMT+0.

Trading prohibitions

The following are prohibited from trading this contract:
Trending markets

A new era of Coinbase has begun

The future of money is here. Be one of the first to get access and try new features the moment they’re available.

Create an account now
FAQs

Discover more

Legal
Prediction markets are offered by Coinbase Financial Markets, a registered futures commission merchant with the Commodity Futures Trading Commission and a Member of the National Futures Association. Trading prediction contracts involve substantial risk and may result in the loss of your entire investment. Contracts pay out only if the specified event occurs. Trade only if you understand the product and believe it is appropriate for your financial situation and objectives.Certain content has been prepared by third parties not affiliated with Coinbase Financial Markets or any of its affiliates and Coinbase is not responsible for such content. Coinbase is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Information is provided for informational purposes only and is not investment advice. This is not a recommendation to buy or sell a particular digital asset or to employ a particular investment strategy. Coinbase makes no representation on the accuracy, suitability, or validity of any information provided or for a particular asset. Prices shown are for illustrative purposes only. Actual cryptocurrency prices and associated stats may vary. Data presented may reflect assets traded on Coinbase’s exchange and select other cryptocurrency exchanges. Past performance is not a reliable indicator of future results.